Cargando…

519. Risk Factor Analysis for Hospital Admission Following Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Monoclonal Antibody Treatment

BACKGROUND: The FDA has issued emergency use authorization (EUA) for neutralizing monoclonal antibodies (mAb) for the treatment of mild-moderate coronavirus disease 2019 (COVID-19) in patients who are at high risk of disease progression. The EUA allows for COVID-19 mAb infusion to occur up to 10 day...

Descripción completa

Detalles Bibliográficos
Autores principales: Abusalem, Lana, Wood, Cole, Crescencio, Juan Carlos Rico, Dare, Ryan K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644710/
http://dx.doi.org/10.1093/ofid/ofab466.718

Ejemplares similares